PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 3, 2026Journal of Gastroenterology1 citationsOpen Access

Immune Checkpoint Inhibitor-Related Pancreatitis: Review of Epidemiology and Management

Immune checkpoint inhibitor-related pancreatitis: a comprehensive review of epidemiology, pathophysiology, and management

View Full Paper
Ask AI
Bookmark
Share

Authors

YLYoonchan LeeDODongwook OhSCSung Hyun Cho

Discussion

Loading...

Member takes

Overview

This comprehensive review explores immune checkpoint inhibitor-related pancreatitis, its management, and implications for cancer treatment.

Key Points

  • This review aims to summarize the epidemiology, pathophysiology, diagnosis, and management of immune checkpoint inhibitor-related pancreatitis.
  • Comprehensive literature review of existing evidence on ICI-related pancreatitis.
  • Analysis of epidemiology and risk factors associated with ICI-P.
  • Discussion of histopathological characteristics and symptoms of ICI-P.
  • Evaluation of management strategies, including corticosteroid use.
  • Incidence of ICI-related pancreatitis ranges from 0.5% to 5.7%, higher with combination immunotherapy.
  • Histopathology shows acinar-centric T cell infiltration shifting from CD4+ to CD8+ cells.
  • Long-term complications include pancreatic atrophy (44-55%), new-onset diabetes, and exocrine insufficiency.
  • Contradictory evidence on corticosteroids suggests they help with acute symptoms but may not affect long-term outcomes.
  • ICI-P may correlate with improved overall survival, indicating enhanced antitumor immunity.

Cite This Study

Lee et al. (2026) studied this question.

synapsesocial.com/papers/69cf5fe05a333a821460eafahttps://doi.org/10.1007/s00535-026-02389-2
View Full Paper
Ask AI
Bookmark
Share